The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges

Author:

Ge Feilin,Yang Yan,Bai Zhaofang,Si Lanlan,Wang Xuemei,Yu Jia,Xiao Xiaohe,Liu Yan,Ren Zhigang

Abstract

AbstractChronic hepatitis B (CHB) remains a major world's most serious public health issues. Despite the remarkable effect of nucleos(t)ide analogues (NAs) in inhibiting hepatitis B virus (HBV) deoxyribonucleic acid (DNA) as the first-line drug, there are several limitations still, such as poor antigen inhibition, drug resistance, low-level viremia, restricting patients' functional cure. Due to the constraints of NAs, traditional medicines, such as traditional Chinese medicine (TCM), have become more prevalently used and researched in the clinical treatment of CHB as complementary alternative therapies. As a consequence, the review focuses on the background based on HBV’s life cycle as well as the NAs’ limitations, progress based on direct and indirect pathway of targeting HBV of TCM, and challenges of TCM. We found TCMs play an increasingly important role in anti-HBV. In a direct antiviral way, they regulate HBV infection, replication, assembly, and other aspects of the HBV life cycle. As for indirect way, TCMs can exert anti-HBV effects through targeting the host, including immune regulation, apoptosis, autophagy, oxidative stress, etc. Especially, TCMs have the advantages of strong antigenic inhibition compared to NAs. Specifically, we can combine the benefits of TCMs in strong HBV antigen inhibition with the benefits of NAs in targeted antiviral effects, in order to find a suitable combination of "TCM + NAs" to contribute to Chinese knowledge of the realisation of the “global elimination of HBV by 2030” goal of the World Health Organization.

Funder

National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Complementary and alternative medicine,Pharmacology

Reference92 articles.

1. Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4:545–58.

2. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B. Infect Dis Info. 2023,36:1–17.

3. Deng W, Jiang TT, Bi XY, et al. Progress on the treatment of chronic hepatitis B with interferons. Chin J liver disea. 2023;15:1–6.

4. China Center for Disease Control and Prevention. Summary of epidemic situation of Class A, B and C infectious diseases in China in March 2022. Dis detect. 2022;37:421.

5. Wang GQ, Liang P, Li P, Tan YH, Bonkovsky HL. The role of traditional Chinese medicines (TCM) and other complementary and alternative medicines (CAM) in the management of chronic hepatitis B. Curr Hepatol Rep. 2019;18:316–21.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3